BridgeBio Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for BridgeBio Pharma (BBIO).

Price Target Range — 10 Quarters

Analyst Consensus — 25 Analysts

23Buy

2Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$94Upside to Avg. PT+41.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$157→$156
Sep 10, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$120
Sep 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$120
Sep 1, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$96→$110
Aug 12, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$102→$107
Aug 12, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$104→$106
Aug 12, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$100→$111
Aug 11, 2026	B of A Securities	Geoff Meacham	PT Raise	Buy	$101→$104
Aug 11, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$95→$110
Aug 11, 2026	Morgan Stanley	Sean Laaman	PT Cut	Overweight	$98→$97
Aug 11, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$111→$115
Aug 11, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$98→$102
Jul 16, 2026	Citigroup	Eric Joseph	PT Raise	Neutral	$82→$93
Jul 13, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$110→$120
Jun 16, 2026	Mizuho	Salim Syed	PT Cut	Outperform	$106→$96
Jun 3, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$104
May 28, 2026	Morgan Stanley	Sean Laaman	PT Raise	Overweight	$94→$98
May 28, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$110
May 26, 2026	Raymond James	Martin Auster	Downgrade	Outperform→Market Perform	—
May 19, 2026	Citigroup	Eric Joseph	Initiate	Neutral	$82

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $157 to $156.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $96 to $110.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $102 to $107.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106

Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $104 to $106.

Benzinga Newsdesk

BridgeBio Pharma Inc

뉴스

파트너 / 기고자

벤징가 글로벌

BridgeBio Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PRO
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

PRO
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

PRO
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106

People Also Watch

People Also Watch

BridgeBio Pharma Inc

뉴스

파트너 / 기고자

벤징가 글로벌

BridgeBio Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

PROHC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PROHC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PROMizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

PROTruist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

PROCanaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

PRO
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

PRO
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

PRO
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106